BioSpace News Archive

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.

Mablink Bioscience (“Mablink”) today announced that preclinical efficacy and safety data on its lead ADC candidate, MBK-103, will be presented at the American Association for Cancer Research (“AACR“) Meeting 2023 on April 17, 2023, in Orlando, Florida.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”) today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced that new data will be presented demonstrating the promise of its SORT1+ Technology™ platform of proprietary peptides, and of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in enabling targeted delivery of anticancer therapy.

Ascentage Pharma (6855.HK) today announced that the latest results from three preclinical studies of the company’s novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023).

Tango Therapeutics, Inc. announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Onchilles Pharma, a private biotech company developing new cancer therapeutics that leverage myeloid biology, announced today the presentation of preclinical data for N17350 at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 at the Orange County Convention Center in Orlando, Florida.

Replicate Bioscience, a company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.